Sage Journals: Discover world-class research

Retricted access

Research article

First published 2022-5

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Michael Zhong, Anneke van der Walt, Jim Stankovich [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2021-1

Severe Delayed-Onset Neutropenia Induced by Ocrelizumab

Jonatha Baird-Gunning, James Yun, William Stevenson [...]

The Neurohospitalist

Retricted access

Review article

First published 2023-6

Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis

Gianmarco Abbadessa, Giuseppina Miele, Elisabetta Maida [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2021-11

Dengue fever in a multiple sclerosis patient taking Ocrelizumab

Tommaso Guerra, Luca Bollo, Maria Trojano [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-1

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis

Shin Yee Chey, Allan G. Kermode

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Case report

First published 2021-10

Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis

Agnieszka Machlańska, Grzegorz Helbig, Karolina Chromik [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2021-1

A possible case of serum sickness after ocrelizumab infusion

Vanessa F Moreira Ferreira, Dorlan J Kimbrough, James M Stankiewicz

Multiple Sclerosis Journal

Retricted access

Research article

First published 2023-9

Immune-mediated colitis associated with ocrelizumab: A new safety risk

Tiffany Kim, Allen Brinker, David Croteau [...]

Multiple Sclerosis Journal

Free access

Case report

First published 2024-1

Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab

Ysoline Beigneux, Celine Louapre, Kevin Bihan [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-10

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Douglas L Arnold, Till Sprenger, Amit Bar-Or [...]

Multiple Sclerosis Journal

Search results